Literature DB >> 1405353

Up-regulated MHC-class II expression and gamma-IFN and soluble IL-2R in lupus nephritis.

H Yokoyama1, T Takabatake, M Takaeda, T Wada, T Naito, K Ikeda, S Goshima, K Takasawa, N Tomosugi, K Kobayashi.   

Abstract

Expression of MHC-class II molecules (HLA-DR and -DQ), serum gamma-interferon (gamma-IFN) and soluble interleukin-2 receptor (sIL-2R) levels were studied in 35 Japanese patients with lupus nephritis (LN) to clarify intraglomerular cellular activation and cytokine involvement in human LN. In 11 normal kidney specimens, HLA-DR(Ia1) was noted in glomerular tufts, but HLA-DQ was either not or was faintly detected in glomeruli by the indirect immunofluorescence technique. HLA-DR and -DQ were observed mainly on the surface of glomerular endothelial cells in 100% and 50% of 28 lupus kidney specimens except for necrotic or sclerotic lesions. HLA-DQ was expressed in a high incidence of 67%, 86% in patients with proliferative LN (WHO Class III-IV) and active lesions, respectively. Serum gamma-IFN and sIL-2R levels were 1.2 +/- 0.2 U/ml and 190 +/- 24 U/ml (mean +/- SEM; N = 30) in normal controls, and elevated in patients with proliferative LN (4.1 +/- 1.0 U/ml, 383 +/- 81 U/ml, N = 25), especially with active lesions (6.2 +/- 1.5 U/ml, 500 +/- 110 U/ml, N = 14). Overall, glomerular lesions such as HLA-DQ expression, the activity index and leukocyte infiltration correlated positively with serum gamma-IFN levels (r = 0.55; P less than 0.01 for HLA-DQ, r = 0.68; P less than 0.001 for activity index, r = 0.38; P less than 0.05 for leukocyte infiltration), but not with serum sIL-2R levels, anti-DNA antibody titers and CH50 titers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405353     DOI: 10.1038/ki.1992.344

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

2.  Protective effect of A at position - 168 in the type III promoter of the MHCIITA gene in systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Hirotaka Kaneko; Chihiro Terai; Naoyuki Kamatani
Journal:  Ann Rheum Dis       Date:  2007-09       Impact factor: 19.103

3.  The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?

Authors:  G Stojan; M Petri
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-07-27

Review 4.  A genomic approach to human autoimmune diseases.

Authors:  Virginia Pascual; Damien Chaussabel; Jacques Banchereau
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 5.  Assessing the human immune system through blood transcriptomics.

Authors:  Damien Chaussabel; Virginia Pascual; Jacques Banchereau
Journal:  BMC Biol       Date:  2010-07-01       Impact factor: 7.431

6.  Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.

Authors:  Ping Chen; Thuy Vu; Adimoolam Narayanan; Winnie Sohn; Jin Wang; Michael Boedigheimer; Andrew A Welcher; Barbara Sullivan; David A Martin; Juan Jose Perez Ruixo; Peiming Ma
Journal:  Pharm Res       Date:  2014-09-12       Impact factor: 4.200

Review 7.  The role of cytokine in the lupus nephritis.

Authors:  Yasunori Iwata; Kengo Furuichi; Shuichi Kaneko; Takashi Wada
Journal:  J Biomed Biotechnol       Date:  2011-10-18

8.  Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production.

Authors:  Manabu Kawamoto; Masayoshi Harigai; Masako Hara; Yasushi Kawaguchi; Katsunari Tezuka; Michi Tanaka; Tomoko Sugiura; Yasuhiro Katsumata; Chikako Fukasawa; Hisae Ichida; Satomi Higami; Naoyuki Kamatani
Journal:  Arthritis Res Ther       Date:  2006-03-22       Impact factor: 5.156

Review 9.  Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis.

Authors:  Susan Yung; Desmond Yh Yap; Tak Mao Chan
Journal:  F1000Res       Date:  2017-06-13

10.  Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis.

Authors:  Michael J Boedigheimer; David A Martin; Zahir Amoura; Jorge Sánchez-Guerrero; Juanita Romero-Diaz; Alan Kivitz; Cynthia Aranow; Tak Mao Chan; Yip Boon Chong; Kit Chiu; Christine Wang; Winnie Sohn; Gregory E Arnold; Michael A Damore; Andrew A Welcher; Barbara A Sullivan; Brian L Kotzin; James B Chung
Journal:  Lupus Sci Med       Date:  2017-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.